Patients undergoing planned interventions should receive written indications of the anticipated dates and times of their interventions and the dates and times by which they should stop taking NOACs and any other medications.
No significant bleeding risk and/or adequate local hemostasis possible: schedule at trough level (i.e., 12 or 24 hours after the last intake). CrCl, creatinine clearance; LMWH, low molecular-weight heparin; UFH, unfractionated heparin; NOAC, non-vitamin K antagonist oral anticoagulants. Non-coronary angiography (for coronary angiography and ACS: see "patients undergoing a planned invasive procedure, surgery or ablation" section)
Pacemaker or ICD implantation (unless in a complex anatomical setting; e.g., congenital heart disease)
Interventions with high bleeding risks (i.e., frequent and/or of high impact) 간이 경과하면 NOAC를 다시 투약할 수 있다 [42] .
응급 수술이 필요한 환자

응급 수술과 같은 처치가 필요한 경우 즉시 NOAC를 중단 해야 한다. 구체적인 환자 관리는 응급 수술의 긴급한 정도
(즉각적, 긴급, 신속)에 따라 달라 질 수 있다 (Fig. 4) . 
즉각 수술
The ranges are the 5-95th percentiles for dabigatran, rivaroxaban, and apixaban; and the interquartile ranges for edoxaban. The reagents used in FXa inhibitor assays affect the PT sensitivity and that of the aPTT in patients given dabigatran. When a sensitive assay is used, a normal aPTT excludes the above on-therapy levels in dabigatran-treated patients, and a normal PT excludes the above on-therapy levels in patients given rivaroxaban or edoxaban, but not apixaban. Point 
